Furthermore, in the indication for use statement for HercepTestTM, it says that the ToGA trial demonstrated that HER2 amplification and protein overexpression are not as correlated as for breast cancer, thus a single method should not be used to determine HER2 status in gastric cancer patients (17). The gene discussed is ERBB2; the disease is breast carcinoma.